LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Janux Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERJANX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / JANX COVERAGE

What’s moving Janux Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Investors are testing whether Janux Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Why Wall Street sees big potential in Janux Therapeutics, Inc. (JANX)

Why Wall Street sees big potential in Janux Therapeutics, Inc. (JANX)

The story matters when it changes Janux Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

Investors are testing whether Janux Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now

Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now

Investors are testing whether Janux Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

Investors are testing whether Janux Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Investors are testing whether Janux Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest JANX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-23 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-11SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-11SEC ↗4Official SEC filingFiled 2026-07-31 · Period 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Janux Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.